Biotest GmbH KGaA (LTS:0N6Z) OCF Yield %: 0.00 (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biotest GmbH KGaA OCF Yield %?

Biotest GmbH KGaA LTS:0N6Z OCF Yield % is 0.00 as of Aug. 12, 2026.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Biotest GmbH KGaA's Trailing 12-Month Cash Flow from Operations is £0.00 Mil, and Market Cap is £0.00 Mil. Therefore, Biotest GmbH KGaA's OCF Yield % for today is 0.00%.

The historical rank and industry rank for Biotest GmbH KGaA's OCF Yield % or its related term are showing as below:


LTS:0N6Z's OCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -8.57
* Ranked among companies with meaningful OCF Yield % only.

Biotest GmbH KGaA's OCF Margin % for the quarter that ended in . 20 was %.

Biotest GmbH KGaA OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Biotest GmbH KGaA OCF Yield % Related Terms

Biotest GmbH KGaA OCF Yield % Historical Data

* Premium members only.

The historical data trend for Biotest GmbH KGaA's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA OCF Yield % Chart

Biotest GmbH KGaA Annual Data
Trend
OCF Yield %

Biotest GmbH KGaA Semi-Annual Data
OCF Yield %

Biotest GmbH KGaA OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Biotest GmbH KGaA's OCF Yield % for the fiscal year that ended in . 20 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
= /
=N/A%

Biotest GmbH KGaA's annualized OCF Yield % for the quarter that ended in . 20 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
= * 1 /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of 0.00 mean?
Biotest GmbH KGaA (LTS:0N6Z) has a OCF Yield % of 0.00 as of Aug. 12, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Biotest GmbH KGaA and its competitors.
Is Biotest GmbH KGaA's OCF Yield % too high?
Biotest GmbH KGaA's current OCF Yield % is 0.00.
How does Biotest GmbH KGaA's OCF Yield % compare to ?
Biotest GmbH KGaA's OCF Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Biotest GmbH KGaA and its competitors. Biotest GmbH KGaA's current OCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current OCF Yield % of 0.00. The current OCF Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current OCF Yield % is 0.00 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest GmbH KGaA Business Description

Comparable Companies
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.